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Loperamide, pimozide, and STF-62247
trigger autophagy-dependent cell death in
glioblastoma cells
Svenja Zielke1, Nina Meyer2, Muriel Mari3, Khalil Abou-El-Ardat4,5,6, Fulvio Reggiori3, Sjoerd J. L. van Wijk1,
Donat Kögel 2 and Simone Fulda 1,5,6
Abstract
Autophagy is a well-described degradation mechanism that promotes cell survival upon nutrient starvation and other
forms of cellular stresses. In addition, there is growing evidence showing that autophagy can exert a lethal function via
autophagic cell death (ACD). As ACD has been implicated in apoptosis-resistant glioblastoma (GBM), there is a high
medical need for identifying novel ACD-inducing drugs. Therefore, we screened a library containing 70 autophagy-
inducing compounds to induce ATG5-dependent cell death in human MZ-54 GBM cells. Here, we identiﬁed three
compounds, i.e. loperamide, pimozide, and STF-62247 that signiﬁcantly induce cell death in several GBM cell lines
compared to CRISPR/Cas9-generated ATG5- or ATG7-deﬁcient cells, pointing to a death-promoting role of autophagy.
Further cell death analyses conducted using pharmacological inhibitors revealed that apoptosis, ferroptosis, and
necroptosis only play minor roles in loperamide-, pimozide- or STF-62247-induced cell death. Intriguingly, these three
compounds induce massive lipidation of the autophagy marker protein LC3B as well as the formation of LC3B puncta,
which are characteristic of autophagy. Furthermore, loperamide, pimozide, and STF-62247 enhance the autophagic
ﬂux in parental MZ-54 cells, but not in ATG5 or ATG7 knockout (KO) MZ-54 cells. In addition, loperamide- and pimozide-
treated cells display a massive formation of autophagosomes and autolysosomes at the ultrastructural level. Finally,
stimulation of autophagy by all three compounds is accompanied by dephosphorylation of mammalian target of
rapamycin complex 1 (mTORC1), a well-known negative regulator of autophagy. In summary, our results indicate that
loperamide, pimozide, and STF-62247 induce ATG5- and ATG7-dependent cell death in GBM cells, which is preceded
by a massive induction of autophagy. These ﬁndings emphasize the lethal function and potential clinical relevance of
hyperactivated autophagy in GBM.
Introduction
GBM represents the most aggressive malignant primary
brain tumor with a median survival of 16 months after
radio-chemotherapy1,2. Importantly, GBMs were shown
to be highly resistant to caspase-dependent apoptosis3,4.
As defects in apoptosis signaling contribute to tumor-
igenesis and chemoresistance, there is a high medical
need for novel therapies5. Therefore, the induction of
alternative forms of cell death, such as ACD has
emerged as an attractive concept to trigger cell death in
GBM6.
Macroautophagy (hereafter autophagy) is a catabolic
process that involves the degradation of cytoplasmic
components, including damaged organelles and protein
aggregates in double-membraned autophagosomes that
eventually fuse with lysosomes to allow cargo
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degradation7. To date, numerous autophagy-related
(ATG) proteins have been characterized in yeast, many
of which have known orthologs in mammals8. ATG
proteins are required for virtually every step of autop-
hagy and autophagosome biogenesis, starting with
nucleation of the initial autophagosome precursor, the
phagophore9. Subsequent membrane expansion, closure
of the autophagosome as well as intralysosomal degra-
dation depend on the concerted action of two ubiquitin-
like conjugation systems, which include ATG5 and
ATG710,11. Well-described marker proteins for mon-
itoring autophagy progression are members of the LC3/
GABARAP protein family12. Soluble LC3/GABARAP is
constitutively processed by ATG4 proteases and, upon
onset of autophagy, becomes conjugated to the phos-
phatidylethanolamine (PE) present in autophagosomal
membranes through the action of the two ubiquitin-like
conjugation systems8,13.
The cellular outcome of autophagy induction is highly
contextual. On the one hand, it is well-described that
autophagy serves to adapt to stressful conditions, such
as nutrient deprivation, oxidative damage or accumu-
lation of misfolded proteins and, thus, promotes cellular
survival14–16. On the other hand, there is growing evi-
dence suggesting a cell death-promoting role of autop-
hagy, referred to as type II cell death or ACD17.
Enforced hyperactivation of autophagy has been
described to trigger massive cellular self-digestion
beyond the point of allowing cellular survival18,19.
Moreover, autophagosomes can serve as signaling plat-
forms that facilitate the activation and integration of
different cell death pathways, such as necroptosis,
through caspase-8 activation on autophagosomal
membranes20. Furthermore, selective degradation of
speciﬁc proteins, like the reactive oxygen species (ROS)
scavenger catalase, can induce ACD as well21.
Several key criteria have been deﬁned for bona ﬁde
ACD. First of all, the term ACD should be limited to
cases of cell death that can be suppressed through either
genetic or pharmacological inhibition of at least two
members of the autophagic core machinery22. Second,
the death process should be mediated via an enhanced
autophagic ﬂux instead of blocking autophagy at any of
its stages23.
Intriguingly, in vitro and in vivo induction of ACD has
been investigated as a potential therapeutic approach in
apoptosis-resistant cancers24–26. Hence, the identiﬁca-
tion of novel ACD-inducing drugs in highly malignant
GBM cells remains a promising strategy. In order to
identify novel inducers of ACD, we screened a com-
pound library containing 70 known autophagy-inducing
drugs on parental as well as ATG5-deﬁcient MZ-54
GBM cells.
Results
Loperamide, pimozide, and STF-62247 induce autophagy-
dependent cell death in GBM cells
To identify novel inducers of ACD we screened the
Enzo Screen-Well™ library containing 70 known
autophagy-inducing drugs for cell death induction in
wild-type (WT) MZ-54 GBM cells and ATG5 or ATG7
KO MZ-54 cells. Using next-generation sequencing we
identiﬁed the heterozygous gain-of-function mutation
ENSP00000391127:p.Arg248Trp within the TP53 gene of
MZ-54 cells, which has been reported to render cells less
sensitive towards apoptosis-inducing drugs27,28. We pre-
viously described the generation of CRISPR/Cas9 ATG5
KO cells derived from the MZ-54 cell line29 (Fig. 1a). Of
note, the ATG5-ATG12 conjugate was found to be absent
not only in ATG5 KO, but also in ATG7 KO cells
(depicted by asterisk), which is in line with the notion that
ATG7 is required for the conjugation of ATG12 to ATG5
during autophagosome maturation30. Importantly, among
the tested compounds we identiﬁed loperamide, pimo-
zide, and STF-62247 to induce ATG5- and ATG7-
dependent cell death in MZ-54 cells at various
concentrations, as loperamide-, pimozide- or STF-62247-
triggered cell death was signiﬁcantly reduced in ATG5 or
ATG7 KO compared to control cells (Fig. 1b–d). As a
positive control, we used the antidepressant drug imi-
pramine hydrochloride (IM) in combination with the
anticoagulant drug ticlopidine (TIC), since this combi-
nation has previously been reported to induce ACD in
GBM cells24. As expected, treatment with IM and TIC
triggered cell death in a concentration-dependent manner
in parental MZ-54 cells, which was signiﬁcantly decreased
in ATG5 or ATG7 KO MZ-54 cells (Fig. 1e). As a negative
control, treating MZ-54 cells with the apoptosis-inducing
compound ABT-737 and etoposide induced cell death in
WT MZ-54 cells to a similar extent as in ATG5 or ATG7
KO cells (Suppl. Fig. S1)31.
Kinetic analysis showed that all compounds induced cell
death in a time-dependent manner (Fig. 2a–d, Suppl. Fig.
S2). KO of ATG5 or ATG7 protected cells from loper-
amide-, pimozide- and IM/TIC-induced cell death after
48 h and from STF-62247-induced cell death after 48 h as
well as 72 h (Fig. 2a–d).
Together, these ﬁndings indicate that autophagy con-
tributes to cell death induced by loperamide, pimozide,
and STF-62247, similarly to IM/TIC.
To investigate whether the induction of autophagy-
dependent cell death by loperamide, pimozide, and STF-
62247 also occurs in other GBM cell lines we extended
our experiments to additional GBM cell lines. Impor-
tantly, loperamide-, pimozide- and STF-62247-induced
cell death was signiﬁcantly reduced in ATG5 or ATG7 KO
LN-229 or U343 GOS-3 cells compared to the
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Fig. 1 Loperamide, pimozide, and STF-62247 induce autophagy-dependent cell death in GBM cells. a Lysates from untreated MZ-54 WT,
ATG5, and ATG7 KO cells were subjected to Western blotting with the indicated antibodies and vinculin as loading control. The asterisk indicates the
absence of the ATG5-ATG12 conjugate in ATG7 KO cells. b–d MZ-54 WT, ATG5 KO, and ATG7 KO cells were treated with indicated concentrations of
loperamide, pimozide, STF-62247, and IM/TIC for 48 h. Cell death was assessed by measuring the PI uptake as fraction of total nuclei determined by
Hoechst counterstaining using high-content ﬂuorescence microscopy. Data are presented as mean and SEM of 3−5 independent experiments
performed in triplicate. Signiﬁcances are calculated against WT cells treated with the same drug concentration. *p < 0.05, **p < 0.01, ***p < 0.001. UT
untreated, LOP loperamide, PIMO pimozide, STF STF-62247, IM imipramine hydrochloride, TIC ticlopidine
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corresponding parental cell lines (Suppl. Fig. S3). This
underscores that loperamide, pimozide, and STF-62247
can induce autophagy-dependent cell death in GBM cells.
Loperamide-, pimozide- or STF-62247-induced cell death
does not primarily involve apoptosis, ferroptosis or
necroptosis
To further understand the type of cell death induced by
exposing MZ-54 cells to loperamide, pimozide, STF-
62247, or IM/TIC cell death was assessed in the absence
or presence of pharmacological inhibitors of apoptosis,
ferroptosis, and necroptosis. Addition of the broad-range
caspase inhibitor zVAD.fmk failed to protect MZ-54 cells
from loperamide-, pimozide- or STF-62247-induced cell
death and only partially rescued cells from IM/TIC-
induced cell death, whereas it completely blocked ABT-
737/etoposide-induced apoptosis used as a positive
control for caspase-dependent cell death (Fig. 3a). Con-
sistently, no caspase-3 activation was detected upon
treatment with loperamide, pimozide, STF-62247 or IM/
TIC in contrast to staurosporine (STS) as a positive
control (Fig. 3b), indicating that loperamide, pimozide,
STF-62247 and IM/TIC induced cell death largely in a
caspase-independent manner. In addition, the ferroptosis
inhibitor ferrostatin-1 (Fer-1) failed to block cell death by
loperamide, pimozide, STF-62247, or IM/TIC, whereas it
efﬁciently blocked cell death induced by the GPX4 inhi-
bitor RSL3 (Fig. 3c) that was used as a positive control
for ferroptosis32. Similarly, addition of the receptor-
interacting protein kinase (RIPK)1 inhibitor necrostatin-
1s (Nec-1s) failed to block cell death induced by
loperamide, pimozide, STF-62247 or IM/TIC, whereas
Nec-1s profoundly protected HT-29 colon carcinoma
















































































































Fig. 2 Loperamide, pimozide, and STF-62247 induce autophagy-dependent cell death of MZ-54 in a time-dependent manner. a–d MZ-54
cells were treated with 17.5 µM loperamide, 15 µM pimozide, 40 µM STF-62247, and 20 µM IM/100 µM TIC for 24, 48, and 72 h. Cell death was
assessed by measuring the PI uptake as fraction of total nuclei determined by Hoechst counterstaining using high-content ﬂuorescence microscopy.
Mean and SEM of 3−5 independent experiments performed in triplicate are shown. Signiﬁcances are calculated versus WT cells. *p < 0.05, **p < 0.01,
***p < 0.001. LOP loperamide, PIMO pimozide, STF STF-62247, IM imipramine hydrochloride, TIC ticlopidine
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necrosis factor (TNF)α, the Smac mimetic BV6 and
zVAD.fmk (Fig. 3d), a well-described model of necrop-
tosis33. Taken together, these ﬁndings indicate that
apoptosis, ferroptosis and necroptosis are not the main
execution pathways during loperamide-, pimozide- and
STF-62247-induced cell death.
Loperamide, pimozide, and STF-62247 induce
dephosphorylation of mTORC1 and S6K
mTORC1 is a well-described negative regulator of
autophagy34. It inhibits this pathway by phosphorylating
few ATG proteins35. mTORC1 itself can be activated
through phosphorylation at Ser2446 by protein kinase B
(PKB), which leads to inhibition of autophagy36,37. Since
this phosphorylation site acts as a switch controlling the
activity and function of mTORC1, we investigated whe-
ther loperamide, pimozide, and STF-62247 induce
dephosphorylation of mTORC1 at Ser2446, as this would
allow for activation of autophagy37. Indeed, loperamide,
pimozide, STF-62247, and IM/TIC markedly reduced
phosphorylation of mTORC1, similar to the well-
described autophagy inducer rapamycin38 (Fig. 4). In
addition, we assessed the phosphorylation status of ribo-
somal protein S6 kinase I (S6K), one of the downstream
targets of mTORC139. In line with the observed depho-
sphorylation of mTORC1, all compounds caused depho-
sphorylation of S6K (Fig. 4). Since rapamycin has been
reported to induce autophagy by preventing phosphor-
ylation of mTORC1 at Ser244634, we tested whether this
drug could also induce autophagy-dependent cell death.
Rapamycin, however, did not induce cell death in MZ-54
cells (Suppl. Fig. S4 A-C) at a concentration that inhibited
phosphorylation of mTORC1 and S6K (Fig. 4). Together,
this set of experiments indicates that loperamide, pimo-
zide, and STF-62247 negatively regulate mTORC1, which
in turn may lead to increased autophagy.
In addition to mTORC1, also ROS are well-known










































































































Fig. 3 Loperamide, pimozide- or STF-62247-induced cell death does not primarily involve apoptosis, ferroptosis, or necroptosis. a, c, d MZ-
54 cells were pretreated for 1 h with 20 µM zVAD.fmk (a), 5 µM Fer-1 (c) or 30 µM Nec-1s (d) followed by treatment with 17.5 µM loperamide, 15 µM
pimozide, 40 µM STF-62247, 20 µM IM/100 µM TIC, 25 µM ABT-737/100 µM etoposide, 500 nM RSL3 or 1 ng/mL TNFα+ 0.5 µM BV6 for 48 h. Cell death
was assessed by measuring the PI uptake as fraction of total nuclei determined by Hoechst counterstaining using high-content ﬂuorescence
microscopy. HT-29 cells served as positive control for induction of necroptotic cell death. b MZ-54 cells were treated with 3 µM STS, 15 µM
loperamide, 15 µM pimozide, 40 µM STF-62247, or 20 µM IM/100 µM TIC for the indicated time points. Caspase-3 activity was determined by
quantifying alterations in Ac-DEVD-AMC ﬂuorescence. Mean and SEM of 3−4 independent experiments performed in triplicate are shown. *p < 0.05,
**p < 0.01, ***p < 0.001. UT untreated, LOP loperamide, PIMO pimozide, STF STF-62247, IM imipramine hydrochloride, TIC ticlopidine, STS
staurosporine
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ROS formation contributes to loperamide, pimozide- and
STF-62247-induced ACD we investigated the effect of
different ROS scavengers, i.e. the water-soluble vitamin E-
derivate trolox, the lipid-soluble vitamin E-derivate α-
tocopherol (α-Toc) and reduced glutathione (GSH)41,42.
The ROS-inducing compound RSL3 was used as a posi-
tive control for ROS-induced cell death43. Preincubation
with α-Toc signiﬁcantly rescued loperamide- and
pimozide-induced cell death of MZ-54 WT and ATG7
KO cells, while trolox and GSH had no effect (Suppl. Fig.
S5 A). Consistently, loperamide and pimozide markedly
triggered ROS production, while STF-62247 slightly
increased ROS levels in WT and ATG7 KO cells (Suppl.
Fig. S5 B). These ﬁndings indicate that loperamide-
and pimozide-induced ACD is associated with ROS
formation.
Loperamide, pimozide, and STF-62247 induce robust
hallmarks of autophagy in GBM cells
To conﬁrm that loperamide, pimozide, and STF-62247
indeed trigger autophagy in MZ-54 cells, we initially
assessed LC3B lipidation as a well-characterized marker
for autophagy44. Indeed, all three compounds as well as
the combination of IM and TIC induced a strong increase
in lipidated LC3B-II levels compared to untreated cells or
cells treated with the apoptosis stimulus ABT-737/eto-
poside that was used as a negative control (Fig. 5a).
Kinetic analysis revealed that LC3B lipidation upon
treatment with loperamide, pimozide, STF-62247, and
IM/TIC occurred in a time-dependent manner (Suppl.
Fig. S6). Strong induction of autophagy occurred 3−6 h
after the addition of loperamide, pimozide, and STF-
62247 as well as 24 h after adding IM/TIC (Suppl. Fig. S6).
Moreover, we conﬁrmed that loperamide, pimozide, and
STF-62247 enhanced LC3B lipidation in LN-229 and
U343 cells as well (Suppl. Fig. S7).
Upon induction of autophagy, LC3 and GABARAP
family proteins associated with expanding phagophores
and autophagosomes appear as distinct puncta-like cyto-
plasmic accumulations which can be assessed by immu-
noﬂuorescence12,45. Therefore, we monitored the
induction of autophagy by immunoﬂuorescent staining of
endogenous LC3B puncta. Notably, treatment of WT
MZ-54 cells with loperamide, pimozide, STF-62247 or
IM/TIC stimulated a strong accumulation of LC3B
compared to a diffuse staining pattern of LC3B in
untreated control cells (Fig. 5b). ABT-737/etoposide
treatment was used as a negative control (Fig. 5b).
Quantiﬁcation revealed a signiﬁcant increase in LC3B
puncta upon treatment with loperamide, pimozide, STF-
62247 or IM/TIC compared to untreated control cells
(Fig. 5c). In contrast, LC3B punctate formation was
almost completely blocked in ATG5 or ATG7 KO MZ-54
cells, as expected (Fig. 5c). This set of experiments
IM/TIC



















Fig. 4 Loperamide, pimozide, and STF-62247 induce dephosphorylation of mTOR and S6K. MZ-54 WT cells were treated with 100 nM
rapamycin, 100 ng/mL EGF, 20 µM IM/100 µM TIC, 17.5 µM loperamide, 15 µM pimozide, or 40 µM STF-62247 for the indicated time points followed
by Western blotting with vinculin as loading control. UT untreated, EGF epidermal growth factor, IM imipramine hydrochloride, TIC ticlopidine, LOP
loperamide, PIMO pimozide, STF STF-62247
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Fig. 5 (See legend on next page.)
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strongly suggests that loperamide, pimozide, and STF-
62247 trigger canonical autophagy in GBM cells.
Loperamide and pimozide induce ultrastructural hallmarks
of autophagy in GBM cells
To further characterize autophagic changes upon
exposure to IM/TIC, loperamide or pimozide, we per-
formed a detailed ultrastructural analysis using electron
microscopy. In contrast to the untreated control, treat-
ment with IM/TIC, loperamide or pimozide induced
massive formation of heteromorphous degradative com-
partments (DGC), which include lysosomes, amphisomes
(i.e. autophagosomes fused with endosomes) and auto-
lysosomes (Fig. 6a–e). In most cases, these DGC con-
tained electron-dense material that likely reﬂects the
presence of cytoplasmic material being degraded. In
addition, we also observed a signiﬁcant increase in
autophagosomes per cell section upon treatment with IM/
TIC, loperamide and pimozide (Fig. 6b, c, e). Notably, the
increase of DGC was shown to be more pronounced than
the increase in autophagosomes, pointing to a rapid
fusion of autophagosomes with lysosomes that is indica-
tive of an enhanced autophagic ﬂux. Together, this
ultrastructural analysis highlights that treatment with IM/
TIC, loperamide and pimozide triggers morphological
hallmarks of autophagy.
Loperamide, pimozide and STF-62247 enhance the
autophagic ﬂux in GBM cells
An increase in autophagosomes can be related either to
an increased autophagic ﬂux or to a block of the
autophagosomal-lysosomal fusion46. To address this point
we treated MZ-54 cells with loperamide, pimozide, STF-
62247 and IM/TIC in the absence and presence of baﬁ-
lomycin A1 (BafA1). Since BafA1 inhibits the acidiﬁcation
of lysosomes and thus the degradation of the autopha-
gosomal cargoes including the members of the LC3 pro-
tein family, enhanced LC3B-II levels upon treatment with
BafA1 reﬂect enhanced stimulation of the autophagic
ﬂux47. Notably, treatment with loperamide, pimozide,
STF-62247 or IM/TIC caused enhanced LC3B lipidation
upon addition of BafA1 compared to treatment in the
absence of BafA1 (Fig. 7a), pointing to an increase in the
autophagic ﬂux.
To accurately corroborate the effects of these com-
pounds on the autophagic ﬂux we used the dual GFP/
RFP-LC3B autophagy ﬂux sensor system that has been
described recently48. This system is based on the
expression of the GFP-LC3B-RFP-LC3BΔG fusion pro-
tein, composed of green ﬂuorescent protein (GFP) fused
to WT LC3B and red ﬂuorescent protein (RFP) fused to
the LC3B Gly120 mutant (Fig. 7b). Upon ectopic
expression, this fusion protein is intracellularly cleaved by
the ATG4 proteases into equimolar ratios (Fig. 7b). GFP-
LC3B localizes to autophagosomes and eventually
becomes partly degraded in autolysosomes upon induc-
tion of autophagy. However, the mutated RFP-LC3BΔG
cannot be conjugated to autophagosomes and remains
cytosolic without being turned over by autophagy, thus
serving as internal control (Fig. 7b). We therefore assessed
GFP and RFP protein levels by Western blotting upon the
induction of autophagy by loperamide, pimozide, and
STF-62247. Importantly, all three compounds led to a
decrease of GFP protein levels, whereas RFP levels
remained stable (Fig. 7c). In contrast, both GFP and RFP
levels remained stable upon compound treatment of
ATG7 KO cells (Fig. 7c).
To conﬁrm these ﬁndings we quantiﬁed GFP/RFP ratios
by ﬂow cytometry. This analysis showed that loperamide,
pimozide, STF-62247, and IM/TIC did indeed reduce the
GFP/RFP ﬂuorescence ratio in WTMZ-54 cells, reﬂecting
an enhancement of the autophagic ﬂux (Fig. 7d). Con-
sistently, the addition of BafA1 prevented the decrease of
the GFP/RFP ratio by preventing lysosomal degradation of
GFP-LC3B (Fig. 7d). In contrast, ATG7 KO MZ-54 cells
expressing the GFP/RFP LC3B sensor did not display
differences in GFP/RFP ratios upon treatment with any of
the compounds (Fig. 7e).
Next, we validated these ﬁndings by ﬂuorescence
microscopy. Indeed, treatment of WT GFP/RFP LC3B
reporter-expressing cells with loperamide, pimozide, STF-
62247, and IM/TIC led to a strong accumulation of dis-
tinct cytoplasmic GFP-positive puncta, likely representing
expanding phagophores or autophagosomes, and an
(see ﬁgure on previous page)
Fig. 5 Loperamide, pimozide, and STF-62247 induce robust hallmarks of autophagy in GBM cells. a MZ-54 cells were treated with 20 µM IM/
100 µM TIC, 17.5 µM loperamide, 15 µM pimozide, 40 µM STF-62247, and 25 µM ABT-737/50 µM etoposide for 24 h followed by detection of vinculin,
ATG7, ATG5, and LC3B protein levels by Western blotting with vinculin as loading control. b MZ-54 cells were treated as indicated in a for 24 h and
the formation of LC3B puncta was imaged using anti-LC3B immunoﬂuorescence staining. Representative images over 25 microscopic views per
sample are shown. c Quantiﬁcation of mean LC3B puncta per cell upon the indicated treatment. Mean and SEM of 3−6 independent experiments
performed for 25 sites per sample are shown. Scale bar= 30 µm. Signiﬁcances after drug treatment of WT, ATG5, and ATG7 KO cells are calculated
versus untreated cells of the corresponding cell line. **p < 0.01, ***p < 0.001. UT untreated, IM imipramine hydrochloride, TIC ticlopidine, LOP
loperamide, PIMO pimozide, STF STF-62247, ABT ABT-737, ETO etoposide
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overall visible decrease of GFP ﬂuorescence, whereas RFP
ﬂuorescence remained stable (Fig. 7f).
In addition, ﬂuorescence microscopy was performed on
MZ-54 cells stably expressing LC3B fused to mRFP and
GFP. Upon induction of autophagy, this mRFP-GFP-
LC3B fusion protein localizes to autophagosomes and
their precursor structures and emits yellow ﬂuores-










































Fig. 6 Loperamide and pimozide induce ultrastructural hallmarks of autophagy in GBM cells. a–d MZ-54 WT cells were left untreated (a, UT) or
treated with 20 µM IM/100 µM TIC (b, IM/TIC), 17.5 µM loperamide (c, LOP) or 15 µM pimozide (d, PIMO) for 48 h before being processed for electron
microscopy. A, autophagosome; D, degradative compartment; E, endosome (early or late); G, Golgi apparatus; M, mitochondria; N, nucleus; PM,
plasma membrane. Scale bar= 1 µm. e The average number of autophagosomes and degradative compartments per cell section was determined as
described in Materials and Methods. Signiﬁcances are calculated versus untreated cells. **p < 0.01, ***p < 0.001. UT untreated, IM imipramine
hydrochloride, TIC ticlopidine, LOP loperamide, PIMO pimozide
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lysosomal lumen, the GFP ﬂuorescence becomes quen-
ched due to the acidic environment, leading to a net
stabilization of red ﬂuorescence signals49. Therefore,
accumulation of red ﬂuorescent signals indicates an
induction of the autophagic ﬂux49. Indeed, treatment with
loperamide, pimozide, STF-62247, or IM/TIC led to a
marked accumulation of yellow and red puncta, repre-
senting autophagosomes and autolysosomes, respectively
(Suppl. Fig. S8 A-B). As expected, addition of BafA1
inhibited the formation of autolysosomes (Suppl. Fig. S8
A-B). Together, these ﬁndings conﬁrm that loperamide,
pimozide, and STF-62247 induce autophagy-dependent
cell death by enhancing the autophagic ﬂux.
Discussion
As ACD has been described as a possible therapeutic
approach in GBM, the identiﬁcation of agents that trigger
ACD has attracted considerable interest6,24,26,29,50,51.
Using CRISPR/Cas9-derived ATG5 and ATG7-deﬁcient
models, we identiﬁed loperamide, pimozide, and STF-
6224 as three novel candidates that induce biochemical
and cellular hallmarks of autophagy and autophagy-
dependent cell death in several GBM cell lines.
Several lines of evidence conﬁrm the induction of
autophagy and subsequent cell death by these com-
pounds. First, biochemical and cellular characteristics of
autophagy as well as cell death induced by loperamide,
pimozide or STF-6224 were signiﬁcantly reduced by
depletion of ATG5 or ATG7 expression. Second, we
demonstrated that loperamide, pimozide, and STF-62247
induced an increase in the autophagic ﬂux of MZ-54 cells
that was potentiated by inhibition of lysosomal matura-
tion and reduced by loss of ATG5 or ATG7 expression.
Third, loperamide- and pimozide-treated MZ-54 cells
were characterized by distinct and prominent ultra-
structural hallmarks of autophagy, which are generally
considered as a gold standard for the analysis of autop-
hagy23. Fourth, we demonstrated that cell death induced
by loperamide, pimozide, and STF-62247 was not pri-
marily mediated via apoptosis, necroptosis or ferroptosis,
as typical pharmacological inhibitors of these cell death
modalities largely failed to prevent cell death. Therefore,
cell death induced by loperamide, pimozide, and STF-
62247 is dependent on autophagy and can be classiﬁed as
ACD17,23,52.
STF-62247 has previously been discovered in a small
molecule-based screen to induce ACD in renal carcinoma
cells53. By performing a screen in a yeast KO collection, a
network of vesicular trafﬁcking between the endoplasmic
reticulum (ER), the trans-Golgi network and lysosomes
was suggested as a target of STF-6224753. Consistent with
this hypothesis, several studies highlighted the relevance
of the trans-Golgi network for autophagosome formation
and the initiation of autophagy54,55.
While both loperamide and pimozide have previously
been reported to stimulate autophagy in a high-
throughput ﬂuorescence microscopy-based screen of H4
GBM cells56, our study is the ﬁrst to show that loperamide
and pimozide trigger ACD. Loperamide is a Food and
Drug Administration (FDA)-approved piperidine derivate
that inhibits voltage-gated L-type calcium (Ca2+) chan-
nels57. Pimozide is an FDA-approved diphenylbutylpi-
peridine that targets D2 dopaminergic receptors58. It is
used in the clinic for the treatment of schizophrenia, but
also as an experimental anticancer drug59,60. Interestingly,
it has been demonstrated that pimozide is a potent inhi-
bitor of low voltage-gated T-type Ca2+ channels61.
In several studies, Ca2+ channel antagonists have been
associated with autophagy regulation; however, their exact
effects on autophagy are still being controversially dis-
cussed62. For instance, an increase in intracellular Ca2+
has been shown to inhibit mTORC1 signaling through
Ca2+/calmodulin-dependent protein kinase 2 (CAMKK2/
CaMKKβ) and AMP-activated protein kinase (AMPK),
leading to accumulation of autophagosomes63. On the
other hand, an inhibitory role of enhanced intracellular
(see ﬁgure on previous page)
Fig. 7 Loperamide, pimozide, and STF-62247 enhance the autophagic ﬂux in MZ-54 cells. a MZ-54 cells were treated with 20 µM IM/100 µM
TIC, 17.5 µM loperamide, 15 µM pimozide, and 40 µM STF-62247 for 8, 2, 4 and 3 h, respectively. BafA1 was added 4 h before cell harvesting at a ﬁnal
concentration of 40 nM. Western blotting was performed with the indicated antibodies and vinculin as loading control. For quantiﬁcation, LC3-II
band intensities were normalized to vinculin band intensities. b Schematic representation of the GFP-LC3B-RFP-LC3BΔG autophagy ﬂux sensor. Upon
expression, the GFP-LC3B-RFP-LC3BΔG fusion protein is cleaved by the ATG4 proteases after which GFP-LC3B becomes conjugated to PE and
localizes to autophagosomes which eventually fuse with lysosomes, inducing degradation of GFP-LC3B. RFP-LC3BΔG remains in the cytosol, where it
serves as internal control. Scheme adapted from Kaizuka et al.48 c Stable GFP-LC3B-RFP-LC3BΔG-expressing MZ-54 WT or ATG7 KO cells were treated
as indicated in a for 16 h followed by Western blotting with vinculin as loading control. d, e Stable GFP-LC3B-RFP-LC3BΔG-expressing MZ-54 WT
(d) or ATG7 KO cells (e) were treated with 20 µM IM/100 µM TIC, 15 µM loperamide, 15 µM pimozide or 40 µM STF-62247 for the indicated time points
followed by ﬂow cytometry. BafA1 was added 4 h before the measurement at a ﬁnal concentration of 40 nM. Mean and SEM of three independent
experiments performed in triplicate are shown. f Fluorescence microscopy of stable GFP-LC3B-RFP-LC3BΔG-expressing MZ-54 WT, ATG5 KO and ATG7
KO cells was performed after 16 h of treatment with 20 µM IM and 100 µM TIC, 17.5 µM loperamide, 15 µM pimozide, and 40 µM STF-62247. Scale bar
= 50 µm. Signiﬁcances are calculated versus untreated cells of the same cell line. *p < 0.05, **p < 0.01, ***p < 0.001. UT untreated, IM imipramine
hydrochloride, TIC ticlopidine, LOP loperamide, PIMO pimozide, STF STF-62247
Zielke et al. Cell Death and Disease  (2018) 9:994 Page 11 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
Ca2+ levels on autophagy has been reported as well.
Increases in Ca2+ activate calpains and adenylate cyclase,
leading to increased levels of 3′-5′-cyclic adenosine
monophosphate (cAMP)64. cAMP stimulates inositol tri-
phosphate (IP3) production that activates inositol 1,4,5-
triphosphate receptors (ITPRs) on the ER membranes to
secrete Ca2+, resulting in autophagy inhibition by main-
taining enhanced mTORC1 activity65. Moreover, Ca2+
release from the ER and the subsequent decrease in intra-
ER Ca2+ levels were shown to promote misfolding of the
lysosomal proton pump vATPase, leading to impaired
lysosomal acidiﬁcation and autophagy66,67. According to
this scenario, inhibition of Ca2+ channels through loper-
amide and pimozide may enhance autophagy indirectly
through a release from autophagy inhibition. Interest-
ingly, apart from enhancing autophagy through lowering
IP3 levels, inhibition of voltage-gated channels has also
been shown to induce autophagy through inhibition of
calpain-mediated cleavage of ATG568.
Moreover, our study suggests that loperamide, pimo-
zide, and STF-62247 regulate autophagy through depho-
sphorylation of mTORC1, a master regulator of
autophagy69. This is consistent with recent ﬁndings
showing that STF-62247 inhibits mTORC170. Loperamide
and pimozide may lead to a decrease in intracellular Ca2+
levels through inhibition of voltage-gated Ca2+ channels.
Interestingly, a rise of intracellular Ca2+ has been repor-
ted to promote binding of Ca2+-bound calmodulin
(CALM) to PIK3C3/VPS34, resulting in mTORC activa-
tion and autophagy suppression71. In line with these
ﬁndings, we observed that loperamide- and pimozide-
induced autophagy is accompanied by dephosphorylation
and inactivation of mTORC1. Furthermore, several stu-
dies highlighted a role for ROS in autophagy induc-
tion15,40. For instance, it was shown that ROS formation
can contribute to ACD while antioxidants can reverse
autophagy, suggesting that ROS formation precedes
autophagy under certain circumstances40,72.
So far, there have been few studies on selective media-
tors of ACD. Recently, glucocerebrosidase (GBA1) has
been identiﬁed by a signalome-wide shRNA-based cell
viability screen as a critical mediator of autophagic self-
consumption and ACD25. Yu et al. reported that autop-
hagy promotes cell death by selective digestion of the ROS
scavenger catalase21. A study by Karch et al. demonstrated
that the BCL-2 family members BAX and BAK are
essential for serum starvation-induced ACD in mouse
embryonic ﬁbroblasts (MEFs) by increasing lysosomal
membrane permeability73. Moreover, TP53 has previously
been shown to regulate sphingosine kinase 1 (SPHK1)-
induced ACD in colon carcinoma cells74.
In recent years, several scenarios have been developed
to explain how increased autophagy can lead to cell death.
The simplest explanation is a threshold effect of
autophagy: in this model, extensive and prolonged
hyperactivation of autophagy triggers cellular self-
digestion via the autophagosomal-lysosomal pathway
beyond the point that allows cell survival18,19,75. Indeed,
our present study shows that loperamide, pimozide, and
STF-62247 induced a strong accumulation of LC3B-
positive autophagosomes and autolysosomes prior to cell
death over a period of 48 h, hence supporting the
hypothesis of a threshold effect which possibly turns
autophagy into a detrimental process. However, it remains
subject to future investigations to identify the pathways
and factors that are responsible for ACD upon treatment
with loperamide, pimozide and STF-62247.
An important prerequisite for the delivery of com-
pounds to brain tumors is their transfer through the blood
−brain barrier, which tightly regulates the passage of
soluble molecules from the blood to the brain76. Pimozide
is used in the clinic for treatment of schizophrenia59,
loperamide was shown to be delivered to the brain when
loaded to polysorbate 80-coated poly(butyl cyanoacrylate)
nanoparticles77 and STF-62247 may well pass the blood
−brain barrier due to its hydrophobic nature and small
size. This suggests that all three compounds may be able
to reach the brain compartment.
In summary, we have identiﬁed in the present study that
loperamide, pimozide, and STF-62247 induce ACD in
GBM cells. Essentially, until now two of these com-
pounds, i.e. loperamide and pimozide, have not been
reported to induce ACD in any cellular model system.
Thus, our study emphasizes the critical role of autophagy
and ACD in GBM cells and provides novel options for the
treatment of these apoptosis-resistant tumors.
Materials and methods
Cell lines and chemicals
The human glioma cell lines MZ-5426,29, LN-229, and
U343 GOS-3 as well as the human colon carcinoma cell
line HT-29 were cultured in DMEM GlutaMAX medium
(Life Technologies, Inc., Eggenstein, Germany) supple-
mented with 10% fetal calf serum (FCS) (Life Technolo-
gies, Inc., Eggenstein, Germany) and 1% penicillin/
streptomycin (Life Technologies, Inc., Eggenstein, Ger-
many) at 37 °C and 5% CO2. Cells were regularly tested for
mycoplasma infection. Cells were authenticated by STR
proﬁling at DSMZ (Sammlung von Mikroorganismen und
Zellkulturen GmbH). Imipramine hydrochloride, ticlopi-
dine, Fer-1, pimozide, epidermal growth factor (EGF),
α-Toc, (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid (trolox) and puromycin were purchased
from Sigma-Aldrich (St. Louis, Missouri, USA). Loper-
amide hydrochloride, rapamycin and STS were purchased
from Enzo Life Sciences (Lausen, Switzerland). STF-
62247 was purchased from Santa Cruz Biotechnology, Inc.
(Dallas, Texas, USA), RSL3 from InterBioScreen
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(InterBioScreen ltd., Russia), etoposide from TEVA
GmbH (Ulm, Germany), ABT-737 from Selleck Chemi-
cals (Houston, Texas, USA) and G418 and reduced GSH
from Carl Roth (Karlsruhe, Germany). The caspase inhi-
bitor zVAD.fmk was purchased from Bachem (Heidel-
berg, Germany) and Nec-1s from Biomol (Hamburg,
Germany). The Smac mimetic BV6 was kindly provided
by Genentech Inc. (South San Francisco, CA, USA).
Recombinant human TNFα was purchased from Bio-
chrom (Berlin, Germany).
Generation of ATG5/7 CRISPR/Cas9 KO cells
To generate ATG5 and ATG7 KO cells, guide RNAs for
ATG5 (MZ-54 ATG5 KO: TCAGGATGAGATAACTG
AAA and CCTCTAATGCTACCACTCAG, U343 ATG5
KO: AAGATGTGCTTCGAGATGTG and CCTCT
AATGCTACCACTCAG) and ATG7 (MZ-54 ATG7 KO:
AATAATGGCGGCAGCTACGG and AAAGCTGACAC
TATACTGG, LN-229 ATG7 KO: AATAATGGCGGC
AGCTACGG and AAGCTGACACTATACTGG) were
cloned into SpCas9(BB)-2A-GFP (PX458) or pSpCas9
(BB)-2A-Puro (PX459) V2.0 from Feng Zhang (Addgene
plasmids #48138 and #62988, respectively) by using BbsI
according to standard cloning procedures78. Plasmids
were veriﬁed using DNA sequencing. Lipofectamine 3000
was used to transfect both ATG5 and ATG7 sgRNAs into
the corresponding GBM cells (DNA/Lipofectamine 3000
ratio 1:1.5) according to the manufacturer’s instructions.
72 h after transfection, SpCas9(BB)-2A-GFP-transfected
cells were sorted into a 24-well plate with an FACS Aria II
cell sorter (BD Biosciences). 48 h after transfection, cells
transfected with pSpCas9(BB)-2A-Puro were selected
with 1 µg/mL puromycin. Next, single cell dilution into
96-well plates was performed using conditioned medium
containing 50% sterile-ﬁltered medium from cultured
cells and 50% fresh medium for 72 h in order to ensure
growth under single cell conditions. ATG5 and ATG7 KO
colonies were expanded and conﬁrmed by PCR analysis
and western blot.
Screening of autophagy-inducing compounds
Parental MZ-54 cells as well as ATG5 KO cells were
seeded at 6500 cells/96-well followed by treatment with
autophagy-inducing compounds of the Enzo Screen-
Well™ library (Enzo Life Sciences, Lausen, Switzerland).
Compounds were added to ﬁnal concentrations between
100 nM and 100 µM. Cell death was assessed after 48 h by
ﬂuorescence-based microscope analysis of propidium
iodide (PI) uptake using Hoechst 33342 and PI double
staining (Sigma-Aldrich, St. Louis, Missouri, USA) as well
as ImageXpress Micro XLS Wideﬁeld High-Content
Analysis System and MetaXpress Software according to
the manufacturer’s instructions (Molecular Devices Sun-
nyvale, CA, USA).
Generation of pMRX-IP-GFP-LC3B-RFP-LC3BΔG-expressing
cells and determination of autophagic ﬂux
Parental MZ-54 and ATG5/7 KO cells were transfected
with pMRX-IP-GFP-LC3B-RFP-LC3BΔG (Addgene plas-
mid # 84572, a gift from Noboru Mizushima48) by using
Lipofectamine 2000 according to the manufacturers’
instructions. 48 h after transfection, cells were selected
with 1 µg/mL puromycin for 7 days. For determination of
autophagic ﬂux, cells were seeded on Greiner black
micro-clear 96-well plates at 10,000 cells/well and imaged
with the ImageXpress Micro XLS Wideﬁeld High-
Content ﬂuorescence microscope (Molecular Devices
Sunnyvale, CA, USA) by using the 60× objective and the
FITC and Texas Red ﬁlter system for imaging of GFP-
LC3B and RFP-LC3BΔG, respectively. Image analysis was
performed with ImageJ (v1.51t).
Generation of mRFP-GFP-LC3B-expressing cells and
measurement of the autophagic ﬂux
Parental MZ-54 and MZ-54 ATG5/7 KO cells were
transfected with the mRFP-GFP-LC3B plasmid (Addgene
#21074) by using Lipofectamine 3000 according to the
manufacturer’s instructions. 48 h after transfection, cells
were selected with 1 mg/mL G418. For determination of
the autophagic ﬂux, cells were seeded into chamber slides
without selection of antibiotic at 12,000 cells/well, treat-
ment was performed as indicated and cells were ﬁxed with
4% paraformaldehyde for 10min followed by ice-cold
methanol for 5 min. After washing with 0.1% triton-X in
phosphate-buffered saline (PBS), cover glasses were ﬁxed
with mounting medium containing DAPI (Dianova,
Hamburg, Germany). Microscope images were taken with
the Nikon Eclipse TE2000-S microscope and NIS Ele-
ments AR 3.2 software (Nikon Instruments Europe BV,
Amsterdam, Netherlands) with 60× magniﬁcation.
Assessment of the autophagic ﬂux by ﬂow cytometry
To determine autophagic ﬂux by FACS, cells stably
expressing pMRX-IP-GFP-LC3B-RFP-LC3BΔG were
pelletized and resuspended in 50 µL of PBS. Measure-
ments were performed with an FACS Accuri ﬂow cyt-
ometer according to the manufacturer’s instructions (BD
Biosciences, Heidelberg, Germany). For calculation of
GFP/RFP ratios, the mean ﬂuorescence intensity (MFI)
ratio of GFP and RFP of untreated WT and ATG7 KO
cells was set to 100%. MFI ratios of compound-treated
samples were then normalized to the corresponding
control cell line.
Determination of cell death
Cell death was measured by ﬂuorescence-based micro-
scope analysis of PI uptake using Hoechst 33342 and PI
double staining (Sigma-Aldrich, St. Louis, Missouri, USA)
and the ImageXpress Micro XLS Wideﬁeld High-Content
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Analysis System and MetaXpress Software according to
the manufacturer’s instructions (Molecular Devices Sun-
nyvale, CA, USA).
Immunoﬂuorescence analyses
For immunoﬂuorescence staining of LC3B, MZ-54 cells
were seeded at 10,000 cells/96-well. For immuno-
ﬂuorescence, cells were ﬁxed with 3.7% paraformaldehyde
for 10min, followed by a washing step with PBS and
permeabilization with 0.1% Triton-X diluted in PBS for
10min. After washing with PBS, cells were blocked with
an antibody dilution buffer (ADB) containing 0.9% NaCl,
10 mM Tris HCl pH 7.5, 5 mM EDTA and 1mg/mL BSA
for 10 min. Cells were incubated with an antibody against
LC3B (Thermo Fisher, PA1-46286) diluted 1:350 in ADB
for 1 h. After three washing steps with 0.1% Tween-20
diluted in PBS (PBS-T), cells were incubated with Cy3TM
AfﬁniPure donkey-a-rabbit IgG (Jackson Immuno
Research Laboratories, Inc.) diluted 1:800 in ADB for 30
min. After three washing steps with PBS-T, Hoechst
33342 was added to the cells diluted 1:15,000 in PBS
followed by image acquisition with the ImageXpress
Micro XLS Wideﬁeld High-Content Analysis System
(Molecular Devices Sunnyvale, CA, USA) by using the
60× objective and the DAPI and TRITC ﬁlter system for
acquisition of Hoechst-stained nuclei and Cy3TM-stained
LC3B, respectively. Image analysis was performed using
ImageJ 1.51t.
Caspase activity assay
For measurement of caspase-3-like activity, 30,000 cells
were seeded per 24-well. Cells were lysed in lysis buffer
containing 10mM HEPES, pH 7.4, 42 mM KCl, 5 mM
MgCl2, 1 mM phenylmethylsulfonyl ﬂuoride, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), 1 μg/
mL pepstatin A, 1 μg/mL leupeptin, 5 μg/mL aprotinin,
0.5% 3-(3-cholamidopropyldimethylammonio)-1-propane
sulfonate (CHAPS). 50 μl of cell lysate were added to
150 µL reaction buffer (25 mM HEPES, 1 mM EDTA,
0.1% CHAPS, 10% sucrose, 3 mM DTT, pH 7.5) con-
taining the ﬂuorigenic substrate Ac-DEVD-AMC (Enzo
Life Sciences, Lausen, Switzerland) at a ﬁnal concentra-
tion of 10 μM. 7-Amino-4-methylcoumarin (AMC)
ﬂuorescence was monitored for 2 h using a Spark multi-
mode microplate reader (Tecan Group AG, Männedorf,
Switzerland). Changes in ﬂuorescence measured over 2 h
were normalized to the total protein content of the lysate.
Caspase activity was expressed as change in ﬂuorescence
units per μg protein and hour.
Electron microscopy
For conventional transmission electron microscopy,
MZ-54 WT cells were treated with the indicated con-
centrations of the compounds. After 48 h, an equal
volume of double strength ﬁxatives (4% paraformalde-
hyde, 4% glutaraldehyde in 0.1M cacodylate buffer
(pH 7.4)) was added to the cells for 20 min at room
temperature, prior to ﬁxing the cells with one volume of
2% paraformaldehyde and 2.5% glutaraldehyde in 0.1M
cacodylate buffer (pH 7.4) for 2 h at room temperature.
Cells were then scraped and embedded as previously
described79. Ultra-thin 70-nm sections were cut using the
Leica EM UC7 ultra microtome (Leica Microsystems,
Wetzlar, Germany) and stained with uranyl acetate and
lead citrate as previously described79. Cell sections were
analyzed using a CM100bio TEM (FEI, Eindhoven,
Netherlands). The average number of autophagosomes
and degradative compartments (amphisomes, lysosomes
and autolysosomes) per cell section was determined by
counting these compartments through 120 cell sections
per condition, randomly selected from ﬁve independent
grids.
Western blot analysis
Western blot analysis was performed as described pre-
viously using RIPA buffer (50 mM Tris-HCl, pH 8, 1%
Triton-X, 0.5% sodium deoxycholate, 150 mM sodium
chloride and 2mM magnesium chloride) supplemented
with Pierce Nuclease (Thermo Fisher, Waltham, MA,
USA)80. The following antibodies were used: monoclonal
rabbit anti-ATG7, rabbit anti-ATG5, rabbit anti-phospho
mTOR (Ser2446), rabbit anti-mTOR, rabbit anti-phospho
S6 Ribosomal Protein (Ser240/244), mouse anti-S6 Ribo-
somal Protein (54D2) (Cell Signaling, Beverly, MA, USA),
mouse anti-vinculin (Sigma, Germany) and rabbit anti-
LC3B (Thermo Fisher, Waltham, MA, USA). Goat anti-
mouse and goat anti-rabbit conjugated to horseradish
peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) as well as enhanced chemiluminescence (Amer-
sham Biosciences, Freiburg, Germany) were used for
detection. Representative blots of at least two independent
experiments are shown. Quantiﬁcation of band intensities
was performed using ImageJ 1.51t.
Determination of ROS production
To analyze ROS production, medium was discarded,
and cells were stained for 30 min at 37 °C with 5 μM CM-
H2DCFDA (Invitrogen). Subsequently, cells were trypsi-
nized and centrifuged for 10min at 4 °C. Supernatant was
discarded and cells were resuspended in phenol red-free
RPMI medium (Life Technologies, Inc.) and immediately
analyzed by ﬂow cytometry.
Statistical analysis
Results are expressed as mean ± SEM. Statistical analy-
sis was performed with SigmaPlot (v12.5). Statistical sig-
niﬁcance of two group data was analyzed by Student’s
t test (two-tailed). If samples did not pass either the
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Shapiro−Wilk Normality Test or the Equal Variance test,
statistical signiﬁcance was analyzed by Mann−Whitney
Rank Sum Test. p values were interpreted as follows:
*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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